Survival rates for lung cancer in Poland

The medical treatment of lung cancer has undergone major changes in the last 15 years. The introduction of targeted therapy for multiple mutations and of immunotherapy for non-oncogene-addicted cases has altered the recommended treatment paradigm. While clinical trials have shown promising results of increased survival, real-world evidence is still scarce.

IHE has entered into a collaboration with the Polish National Cancer Registry to explore the possibility of analyzing and providing detailed estimates of national survival rates for lung cancer by histological subtype and by stage at diagnosis. The results can be downloaded in the report below.

Lung cancer survival rates in Poland (update)

For more information please contact Thomas Hofmarcher